AUTEN-67

AUTEN-67
Clinical data
ATC code	None;
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name N-[3-(1H-Benzimidazol-1-yl)-1,4-dioxo-1,4-dihydro-2-naphthalenyl]-4-nitrobenzenesulfonamide;
CAS Number	301154-74-5 ;
PubChem CID	2324086;
ChemSpider	1736536;
UNII	G53CH4RJ72;
Chemical and physical data
Formula	C23H14N4O6S
Molar mass	474.45 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c1ccc2c(c1)C(=O)C(=C(C2=O)n3cnc4c3cccc4)NS(=O)(=O)c5ccc(cc5)[N+](=O)[O-];
	InChI InChI=1S/C23H14N4O6S/c28-22-16-5-1-2-6-17(16)23(29)21(26-13-24-18-7-3-4-8-19(18)26)20(22)25-34(32,33)15-11-9-14(10-12-15)27(30)31/h1-13,25H; Key:FSAINSJUQREKEK-UHFFFAOYSA-N;

AUTEN-67 is an autophagy-enhancing drug candidate that increases autophagic flux in cell lines and in vivo models.^[1]

It hampers the progression of neurodegenerative symptoms in a Drosophila model of Huntington's disease.^[2] It is developed by Velgene Biotechnology Ltd.

References

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.